Dexcom's 15-Day G7 CGM Wins Health Canada Authorization With 8.0% MARD Accuracy
The industry-leading 15.5-day wear time cuts per-day cost and sensor changes for Canada's 4 million people living with diabetes — and sharpens the competitive edge against Abbott's FreeStyle Libre.
Health Canada has authorized the Dexcom G7 15 Day continuous glucose monitoring system for adults 18 and older with diabetes, Dexcom announced July 13. Availability details will come closer to the Canadian launch; the same product launched in the US on December 1, 2025.
The system's 15.5-day wear time — which Dexcom bills as industry-leading — extends sensor life from the G7's original 10 days, with 8.0% MARD accuracy, a 12-hour sensor-replacement grace period, and direct-to-Apple Watch connectivity.
The stakes in Canada and beyond
More than 4 million Canadians live with diabetes, and longer-wear sensors matter on two fronts: the economics of diabetes management for payers and patients, and the growing consumer and over-the-counter CGM market, where friction — how often you must apply a new sensor — directly shapes adherence.
Dexcom, which cites more than 25 years in glucose monitoring, is simultaneously phasing out the older G6 platform, with production ending in 2026. The 15-day authorization cadence across markets is the company's clearest competitive lever against Abbott's FreeStyle Libre line — and a reminder that in wearable diagnostics, regulatory throughput is product strategy.
Reporting: Dexcom press release via Business Wire, July 13, 2026.
Source
Original reporting: Business Wire / Dexcom ↗